Omalizumab: A review of its use in the treatment of allergic asthma

BioDrugs

Volumn 22, Issue 3, 2008, Pages 189-204

  Plosker, Greg L ^a   Keam, Susan J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Allergic asthma; Omalizumab, pharmacodynamics; Omalizumab, pharmacokinetics; Omalizumab, therapeutic use

Indexed keywords

BECLOMETASONE DIPROPIONATE; CORTICOSTEROID; FLUTICASONE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G ANTIBODY; OMALIZUMAB; PLACEBO;

ADD ON THERAPY; ADOLESCENT DISEASE; ALLERGIC ASTHMA; ANAPHYLAXIS; ANTIGEN BINDING; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; ERYTHEMA; HEADACHE; HUMAN; INCIDENCE; INJECTION SITE PAIN; INJECTION SITE REACTION; OUTCOMES RESEARCH; PHARYNGITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; REVIEW; RHINITIS; SCORING SYSTEM; SIDE EFFECT; SINUSITIS; STATISTICAL SIGNIFICANCE; SWELLING; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

ANIMALS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; CLINICAL TRIALS AS TOPIC; ECONOMICS, PHARMACEUTICAL; HUMANS; QUALITY OF LIFE;

EID: 43749116168     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200822030-00005     Document Type: Review

References (67)

1. Global Initiative for Asthma: global strategy for asthma management and prevention 2007 (update) [online]. Available from URL: http://www.ginasthma.com [Accessed 2008 Jan 7]
2. National Heart Lung and Blood Institute. National Asthma Education and Prevention Program Expert Panel Report 3. Guidelines for the diagnosis and management of asthma (summary report 2007) [online]. Available from URL: http://www.nhlbi.nih.gov/guidelines/asthma/asthmasumm.pdf [Accessed 2008 Jan 8]
3. British Thoracic Society. British guideline on the management of asthma: a national clinical guideline (revised July 2007) [online]. Available from URL: http://www.sign.ac.uk/pdf/sign63.pdf [Accessed 2008 Jan 8]
4. European Medicines Agency. Xolair: summary of product characteristics [online]. Available from URL: http://www.emea [Accessed 2007 Dec 19]
5. Xolair® (omalizumab): US prescribing information. San Francisco (CA): Genentech, Inc. 2007 Jul
6. Bang LM, Plosker GL. Omalizumab: a review of its use in the management of allergic asthma. Treat Respir Med 2004; 3 (3): 183-99
7. Soresi S, Togias A. Mechanisms of action of anti-immunoglobulin E therapy. Allergy Asthma Proc 2006 Mar-Apr; 27 (2 Suppl. 1): S15-23
8. Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001 Aug; 18 (2): 254-61
9. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001 Aug; 108 (2): 184-90
10. Gomez G, Jogie-Brahim S, Shima M, et al. Omalizumab reverses the phenotypic and functional effects of IgE-enhanced Fc?RI on human skin mast cells. J Immunol 2007 Jul 15; 179 (2): 1353-61
11. Beck LA, Marcotte GV, MacGlashan Jr D, et al. Omalizumab-induced reductions in mast cell FCεRI expression and function. J Allergy Clin Immunol 2004; 114: 527-30
12. Djukanovic R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004 Sep 15; 170 (6): 583-93
13. Noga O, Hanf G, Brachmann I, et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol 2006 Jun; 117 (6): 1493-9
14. Noga O, Hanf G, Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol 2003; 131 (1): 46-52
15. Prieto L, Gutiérrez V, Colás C, et al. Effect of omalizumab on adenosine 5′-monophosphate responsiveness in subjects with allergic asthma. Int Arch Allergy Immunol 2006; 139 (2): 122-31
16. Hayashi N, Tsukamoto Y, Sallas WM, et al. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol 2007 May; 63 (5): 548-61
17. Meno-Tetang GML, Lowe PJ. On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach. Basic Clin Pharmacol Tox 2005; 96: 182-92
18. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005 Mar; 60 (3): 309-16
19. Holgate ST, Chuchalin AG, Hébert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34: 632-8
20. Ayres JG, Higgins B, Chilvers ER, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004 Jul; 59 (7): 701-8
21. Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004 Jul; 59 (7): 709-17
22. Berger W, Gupta N, McAlary M, et al. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol 2003 Aug; 91 (2): 182-8
23. Milgrom H, Massanari M, Maykut RJ, et al. Addition of omalizumab reduces school absenteeism in children with moderate-severe persistent asthma [ab1. stract no. 590]. J Allergy Clin Immunol 2007 Jan; 119 (1 Suppl.): S150
24. Milgrom H, Fick Jr RB, Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med 1999 Dec 23; 341 (26): 1966-73
25. Bleecker E, Rubinfield A, Hedgecock S, et al. Add-on omalizumab therapy significantly improves symptom control and reduces exacerbations in patients with inadequately controlled severe persistent asthma despite GINA 2002 step 4 therapy irrespective of maintenance oral corticosteroid (OCS) use: INNOVATE [abstract]. Proceedings of the American Thoracic Society 2005; 2 (Abstr. Suppl.): A359
26. Massanari M, Zeldin R, Maykut R, et al. Omalizumab improves lung function and treatment effectiveness in patients with moderate-severe asthma receiving fluticasone 500mcg/salmeterol 50mcg [abstract]. Proceedings of the American Thoracic Society 2006 Apr; 3 (Abstr. Suppl.): A590
27. Massanari M, Maykut RJ, Kianifard F, et al. Addition of omalizumab improves quality of life in moderate-severe asthmatics receiving fluticasone 500 ug/salmeterol 50 ug [abstract no. 15]. J Allergy Clin Immunol 2007 Jan; 119 (1 Suppl.): S4
28. Massanari M, Kianifard F, Maykut R, et al. Omalizumab reduced need for steroid bursts and improved treatment effectiveness in asthmatics on inhaled salmeterol and fluticasone combination therapy [abstract no. 38]. J Allergy Clin Immunol 2006 Feb; 117 (2 Suppl.): S10
29. Massanari M, Hedgecock S, Fox H, et al. Add-on omalizumab to current asthma therapy substantially decreased the risk of future exacerbations when given after hospitalization due to a severe exacerbation [abstract no. C110]. Proceedings of the American Thoracic Society 2006 Apr; 3 (Abstr. Suppl.): A590
30. Slavin R, Lowe P, Ferioli C, et al. Exploring the effect on asthma control of omalizumab reduction after 28 weeks treatment in responders and non-responders [abstract]. Am J Respir Crit Care Med 2007 Apr; 175 (Abstr. Suppl.): A58
31. Berger W, Humbert M, Leighton T, et al. Asthma patients judged by the physician to have responded to add-on omalizumab therapy have a greater percentage of symptom-free days [abstract]. Proceedings of the American Thoracic Society 2006 Apr; 3 (Abstr. Suppl.): A591
32. Walker S, Monteil M, Phelan K, et al. Anti-IgE for chronic asthma in adults and children (review). Cochrane Database Syst Rev 2006; (2): CD003559
33. Buhl R, Solèr M, Matz J, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002 Jul; 20 (1): 73-8
34. Lanier BQ, Corren J, Lumry W, et al. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 2003; 91: 154-9
35. Chung KF, Ankerst J, Rolli M, et al. Long-term asthma control with omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma [abstract no. 417]. European Respiratory Congress; 2005 Sep 17-21; Copenhagen
36. Chung K, Holgate S, Rolli M, et al. Omalizumab demonstrates long-term asthma control, safety and tolerability in patients with severe immunoglobulin E-mediated allergic asthma [abstract no. 574]. Allergy 2007; 62 Suppl. 83: 210
37. Chung K, Niven R, Panahloo Z, et al. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic (immunoglobulin E-mediated) asthma: a subgroup analysis of an open label trial [abstract no. 383]. Allergy 2007; 62 Suppl. 83: 144-5
38. Finn A, Gross G, van Bavel J, et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 2003 Feb; 111 (2): 278-84
39. Buhl R, Hanf G, Solèr M, et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 2002 Nov; 20 (5): 1088-94
40. Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005 Mar; 60 (3): 302-8
41. Busse WW, Massanari M, Kianifard F, et al. Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis. Curr Med Res Opin 2007 Aug 20; 23 (10): 2379-86
42. Chipps B, Buhl R, Beeh KM, et al. Improvement in quality of life with omalizumab in patients with severe allergic asthma. Curr Med Res Opin 2006 Nov; 22 (11): 2201-8
43. Niebauer K, Dewilde S, Fox-Rushby J, et al. Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma. Ann Allergy IgE-Asthma Immunol 2006 Feb; 96 (2): 316-26
44. Humbert M, Boulet L, Panahloo Z, et al. Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis [abstract no. 371]. Allergy 2007; 62 Suppl. 83: 140-1
45. Deniz YM, Gupta N. Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibody. Clin Rev Allergy Immunol 2005 Aug; 29 (1): 31-48
46. Cox L, Platts-Mills TAE, Finegold I, et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 2007 Dec; 120 (6): 1373-7
47. Krishnan JA, Gould M. Omalizumab for severe allergic asthma: dollars and sense. J Allergy Clin Immunol 2007 Nov; 120 (5): 1015-7
48. Sullivan SD, Turk F. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma. Allergy 2008 Jun; 63 (6): 670-84
49. Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol 2004 Aug; 114 (2): 265-9
50. Brown R, Turk F, Dale P, et al. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy 2007 Feb; 62 (2): 149-53
51. Dewilde S, Turk F, Tambour M, et al. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin 2006 Sep; 22 (9): 1765-76
52. Wu AC, Paltiel AD, Kuntz KM, et al. Cost-effectiveness of omalizumab in adults with severe asthma: results the Asthma Policy Model. J Allergy Clin Immunol 2007 Nov; 120 (5): 1146-52
53. Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003 Jul 28; 163: 1637-41
54. Eichler H-G, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004; 7 (5): 518-28
55. Jönsson B. Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds. Pharmacoeconomics 2004; 22 Suppl. 4: 5-10
56. Busse WW. Expert panel report 3 (EPR-3): guidelines for the diagnosis and management of asthma - summary report 2007. National Asthma Education and Prevention Program. J Allergy Clin Immunol 2007 Nov; 120 (5): S94-S138
57. Johansson SG, Öman H, Nopp A, et al. The importance of IgE antibody levels in anti-IgE treatment. Allergy 2006 Oct; 61 (10): 1216-9
58. Walters EH, Walters JA, Wood-Baker R. Anti-IgE and chemotherapy: a critical appraisal of treatment options for severe asthma. Expert Opin Pharmacother 2007 Apr; 8 (5): 585-92
59. Marcus P. Incorporating anti-IgE (omalizumab) therapy into pulmonary medicine practice: practice management implications. Chest 2006 Feb; 129 (2): 466-74
60. Baumel MJ, Du Buske L, Szefler SJ, et al. National guidelines for a novel therapy: update on clinical trials and experience using consensus panel recommendations for incorporating omalizumab into asthma management. PT 2006 May; 31 (5): 276-82
61. Chapman KR, Cartier A, Hébert J, et al. The role of omalizumab in the treatment of severe allergic asthma. Can Respir J 2006 Jul-2006 31; 13 Suppl. B: 1B-9B
62. Kelly HW. Rationale for the major changes in the pharmacotherapy section of the National Asthma Education and Prevention Program guidelines. J Allergy Clin Immunol 2007 Nov; 120 (5): 989-94; quiz 995-6
63. Belliveau PP, Lahoz MR. Treating allergic asthma with omalizumab. Dis Manage Health Outcomes 2007; 15 (3): 165-79
64. Bousquet J, Wenzel S, Holgate S, et al. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004; 125: 1378-86
65. Bousquet J, Rabe K, Humbert M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007 Jul; 101 (7): 1483-92
66. Nopp A, Johansson SGO, Ankerst J, et al. CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment. Allergy 2007 Oct; 62 (10): 1175-81
67. Chang TW, Wu PC, Hsu CL, et al. Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases. Adv Immunol 2007; 93: 63-119